ENTITY
Keymed Biosciences

Keymed Biosciences (2162 HK)

104
Analysis
Health Care • China
Keymed Biosciences is a biotechnology company focused on the in-house discovery and development of innovative biological therapies for autoimmune diseases and oncology. Their pipeline includes over 50 programs, with key products like Kangyueda® (Stapokibart, CM310) for atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis. The company was founded in 2016 and is headquartered in Chengdu, China.
more
•26 Sep 2026 14:08

China Healthcare Weekly Wrap (21-25 Sep)

We highlight 1) key studies to watch for upcoming October's ESMO updates, 2) deal flows Innocare/Lilly, BoomRay/Novartis, Earendil Labs...

Logo
95 Views
Share
•12 Sep 2026 21:37

China Healthcare Weekly Wrap (7-11 Sep)

1) Insilico AI drug could slow aging indicated by early data; 2) Genscript US$300m placing for AIDD capex; 3) two long-acting TSLP-targeting drugs...

Logo
88 Views
Share
•06 Sep 2026 08:30

APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia

Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...

Logo
103 Views
Share
•03 Sep 2026 13:04

China Biotech/Pharma Sector: 1H26 Results Wrap and Pipeline Catalyst Table

We track 36 major commercial-stage biotech/pharma companies in China for key takeaways/readthroughs and updated sector's major pipeline catalysts...

Logo
112 Views
Share
•24 Aug 2026 10:03

BUY/SELL/HOLD: Hong Kong Market Update (August 2026)

The Hong Kong market continues to show gains on the back of a strong July.  The standout sectors this month include materials and healthcare.

Logo
104 Views
Share
x